Sage Therapeutics Cash Flow Statement

Financials in millions IDR. Fiscal year is January - December.

Millions IDR. Fiscal year is Jan - Dec.

Fiscal Year	TTM	FY 2024	FY 2023	FY 2022	FY 2021	FY 2020	2019
Period Ending	Jun '25 Jun 30, 2025	Dec '24 Dec 31, 2024	Dec '23 Dec 31, 2023	Dec '22 Dec 31, 2022	Dec '21 Dec 31, 2021	Dec '20 Dec 31, 2020	2019
Net Income	-3,138	77.28	4,772	11,703	4,879	-3,138	Upgrade
Depreciation & Amortization	274.02	274.02	95.35	44.36	81.25	87.58	Upgrade
Other Operating Activities	938.86	-9,023	-153,560	-10,016	-9,292	-5,487	Upgrade
Operating Cash Flow	-1,925	-8,671	-148,693	1,732	-4,331	-8,537	Upgrade
Cash Acquisitions	-	-	-	-124.5	-	-	Upgrade
Sale (Purchase) of Real Estate	-	-	-10,009	-	-	-	Upgrade
Investing Cash Flow	-	-	-10,009	-124.5	-	-	Upgrade
Long-Term Debt Issued	-	13,035	13,715	-	6,627	5,600	Upgrade
Short-Term Debt Repaid	-	-	-	-	-	-71.59	Upgrade
Long-Term Debt Repaid	-	-4,538	-9,703	-1,449	-3,746	-107,921	Upgrade
Total Debt Repaid	-4,542	-4,538	-9,703	-1,449	-3,746	-107,993	Upgrade
Net Debt Issued (Repaid)	1,058	8,497	4,012	-1,449	2,881	-102,393	Upgrade
Issuance of Common Stock	28.95	1.06	161,001	-	-	112,465	Upgrade
Other Financing Activities	-	-	-5,709	-	-	-	Upgrade
Financing Cash Flow	1,087	8,498	159,305	-1,449	2,881	10,072	Upgrade
Net Cash Flow	-837.78	-173.25	602.91	158.2	-1,450	1,535	Upgrade
Cash Income Tax Paid	675.37	675.37	554.53	44.5	924.57	-	Upgrade
Levered Free Cash Flow	7,198	-2,138	-145,972	-525.34	1,917	115,735	Upgrade
Unlevered Free Cash Flow	7,198	-2,138	-145,972	-525.34	1,917	115,736	Upgrade

Updated Apr 29, 2025. Source: S&P Global Market Intelligence. Standard template. Financial Sources.

SEC Filings: 10-K · 10-Q